LivaNova (LIVN) Upgraded to Overweight by KeyBanc

Company Overview - LivaNova PLC (NASDAQ:LIVN) is a medical technology company specializing in cardiovascular and neuromodulation solutions, including heart-lung machines, oxygenators, and VNS therapy systems [4] Analyst Ratings - KeyBanc Capital Markets analyst Brett Fishbin upgraded LivaNova's rating from Sector Weight to Overweight, setting a target price of $81, indicating an upside potential of nearly 27% [1] - Goldman Sachs analyst David Roman maintained a Neutral rating on LivaNova but raised the price target from $56 to $66, expecting valuations to align more closely with fundamentals by 2026 [3] Market Trends - KeyBanc's outlook for the Medical Technology segment in 2026 suggests sustainable underlying trends and a diminished valuation premium, creating favorable conditions for stock picking [2]